Skip to main content
Terug
Watch Compare

OS Therapies Inc

Datakwaliteit: 83%
OSTX
NYSE Manufacturing Chemicals
€ 1,30
▼ € 0,05 (-3,70%)
Marktkapitalisatie: 54,02 M
Prijs
€ 1,34
Marktkapitalisatie
54,02 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Debt/Equity of 0,03 — conservative balance sheet
Negative free cash flow of -14,24 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-670,19%
Onder sectorgemiddelde (-53,34%)
ROIC-382,41%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,03
Onder sectorgemiddelde (0,31)
Current Ratio0,56
Interest Coverage-13,99

Waardering

PE (TTM)
-1,88
Onder sectorgemiddelde (-1,47)
P/B Ratio14,85
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,9 -1,5
P/B 14,9 1,6
ROE % -670,2 -53,3
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E 0,0 0,3

Koersdoel Analisten

5 analisten
Buy
Huidig
€ 1,30
+737.5%
Koersdoel
€ 10,89
€ 6,00
€ 8,00
€ 20,00
Vooruitzicht
Forward K/W -4,59
Forward WPA -€ 0,28
Omzet Sch. 29,71 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,28
-€ 0,66 – -€ 0,01
 29,71 M 3
FY2026 -€ 0,43
-€ 0,65 – -€ 0,16
 3,56 M 4

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,14 -€ 0,41 -192,9%
Q32025 -€ 0,12 -€ 0,21 -71,4%
Q22025 -€ 0,12 -€ 0,19 -62,9%
Q12025 -€ 0,09 -€ 0,18 -107,7%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -28,75 M
ROE -670,19% ROA -298,53%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14,24 M
ROIC -382,41% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,03 Current Ratio 0,56
Interest Coverage -13,99 Asset Turnover N/A
Working Capital -1,82 M Tangible Book Value -3,23 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,88 Forward P/E N/A
P/B Ratio 14,85 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -26,36%
Market Cap 54,02 M Enterprise Value 54,12 M
Per Share
EPS (Diluted TTM) -0,98 Revenue / Share N/A
FCF / Share -0,35 OCF / Share -0,35
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 49,52%
SBC-Adj. FCF -16,90 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue — —
Net Income -28,75 M -8,88 M
EPS (Diluted) -0,98 -0,88
Gross Profit — —
Operating Income -28,71 M -6,81 M
EBITDA — —
R&D Expenses 16,36 M 2,84 M
SG&A Expenses — —
D&A 363.085,0 —
Interest Expense 2,05 M 2,05 M
Income Tax — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 6,84 M 5,54 M
Total Liabilities 11,86 M 4,73 M
Shareholders' Equity -6,10 M -5,24 M
Total Debt 100.000,0 100.000,0
Cash & Equivalents — —
Current Assets 332.912,0 5,53 M
Current Liabilities 11,76 M 4,63 M